Evidence map›Paper›PMID 29084917›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, Michael Dallas, Dawson Knoblock, Jean D Boyer, Jian Yan, Russell Vang, Amir S Khan, Laurent Humeau and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Trial
  3. Article
  4. Viral vector-based therapeutic HPV vaccines.Clinical and experimental medicine · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Regulatory Considerations on the Development of mRNA Vaccines.Current topics in microbiology and immunology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. The perfect personalized cancer therapy: cancer vaccines against neoantigens.Journal of experimental & clinical cancer research : CR · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Matthew P Morrow *Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania. mmorrow@invoio.com.
Kimberly A Kraynyak *Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Albert J SylvesterInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Michael DallasInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Dawson KnoblockInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Jean D BoyerInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Jian YanInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Russell VangJohns Hopkins University, School of Medicine, Baltimore, Maryland.
Amir S KhanInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Laurent HumeauInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Niranjan Y SardesaiInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
J Joseph KimInovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Stanley PlotkinThe University of Pennsylvania, Philadelphia, Pennsylvania.
David B WeinerThe Wistar Institute, Philadelphia, Pennsylvania.
Cornelia L Trimble *Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Mark L Bagarazzi *Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Johns Hopkins University · USThe Wistar Institute · USUniversity of Baltimore · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
NCI NIH HHS P50 CA098252
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Human papillomavirus 16Human papillomavirus 18BiomarkersBiopsyCD8-Positive T-LymphocytesDisease ProgressionFemaleGenotypeHumansImmunohistochemistryImmunotherapyIn Situ HybridizationPapillomavirus InfectionsPapillomavirus VaccinesPrognosisTreatment OutcomeBiomarkersPapillomavirus VaccinesVaccines, DNAVGX-3100

Identifiers

PMID29084917
PMCPMC6956401
OpenAlexW2765931561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.